Trial Profile
A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Denosumab (Primary)
- Indications Metabolic bone diseases; Postmenopausal osteoporosis
- Focus Pharmacodynamics
- Sponsors Amgen
- 16 Sep 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Jun 2010 Planned end date changed from 1 Mar 2010 to 1 Aug 2010 as reported by ClinicalTrials.gov.
- 10 Jun 2010 Status changed from not yet recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.